The incidence of hematological malignant tumor is increasing year by year, and seriously affecting the human health. In addition to the traditional radiation and chemotherapy, immunotherapy has achieved a certain effect in the treatment of blood tumor, but it is limited by exhaustion of CD8+ T cell. The exhaustion of CD8+ T cells is mainly related to the activation of some immune checkpoint inhibitors, such as (Tim3), programmed death 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), etc. Among them, Tim3 is getting more and more attention. The combination of Tim3 and its ligand galectin-9 produced a strong cellular immunosuppressive effect. Tim3 has been proved to be associated with CD8+ T cell exhaustion in many tumors. In this review, the application of Tim3/galectin-9 in hematologic tumors is briefly summarized so as to provide theoretical basis for clinical diagnosis and treatment of these diseases.
题目: Tim3/galectin-9在血液系统肿瘤中的研究进展.
摘要: 血液系统肿瘤发病率呈逐年增高趋势，严重影响人类的健康。除传统放化疗外，免疫治疗已在血液肿瘤的治疗中取得了一定的疗效，但是却受到CD8+T细胞衰竭的限制，而CD8+T细胞衰竭主要与一些免疫检查点抑制剂的激活相关，如T细胞免疫球蛋白和粘蛋白域3（Tim3）、程序性死亡-1（PD-1）、细胞毒性T淋巴细胞抗原4（CTLA-4）等。其中，Tim3受到了越来越多的关注。Tim3与它的配体半乳糖凝集素-9（galectin-9）结合，产生了很强的细胞免疫抑制作用。在许多肿瘤中，Tim3被认为与CD8+T细胞衰竭有关。本文拟对Tim3/galectin-9在血液系统肿瘤中的应用进展作一综述，为临床诊治该类疾病提供理论依据.